TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The FDA is requiring manufacturers of all glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications to add a warning about a potential increased risk of non-arteritic anterior ischemic optic neuropathy, or NAION. The agency says the condition is rare but can cause sudden, painless vision loss in one eye, sometimes permanently; it advises patients to seek prompt medical attention for vision symptoms.
The U.S. Food and Drug Administration is requiring manufacturers of all GLP-1 receptor agonist medications to add information about a potential increased risk of NAION, a rare eye condition that can cause sudden, painless vision loss in one eye. The agency’s safety communication advises patients to contact a health care professional promptly if they develop sudden vision changes and advises clinicians to arrange an ophthalmology evaluation when NAION is suspected.
The FDA said the new information must be added to the Warnings and Precautions section of labeling for all GLP-1 RA medications. The communication describes an association with a potential increased risk; it does not say that the medicines have been proven to cause NAION. The source notice does not provide a rate of occurrence or quantify the size of any increase in risk.
NAION involves decreased blood flow to the front of the optic nerve, called the optic disc. The FDA says it can result in acute, painless decreased vision in one eye, including permanent vision loss. Symptoms described in the notice include sudden vision loss, blurred or missing areas of vision, blind spots or tunnel vision, distorted colors, and reduced sharpness in the center of vision.
The agency advises patients and caregivers to contact a health care professional right away if these symptoms occur. Anyone who has experienced NAION should discuss whether to continue or stop a GLP-1 RA with their clinician. For clinicians, the FDA recommends prompt referral to an ophthalmologist when NAION is suspected and says to consider discontinuing the drug in patients who develop the condition, unless treatment benefits clearly outweigh the risk.
What the Label Warning Changes
The required wording adds a potential vision-related risk to medication labeling used by patients, prescribers and pharmacists. It provides information relevant to symptom recognition and treatment discussions. The FDA’s communication advises prompt evaluation of vision symptoms; it does not recommend that all patients stop treatment.
GLP-1 RAs are used to treat type 2 diabetes and to reduce excess body weight and maintain weight reduction. The warning applies to people taking these medicines and to health professionals who prescribe or dispense them. The notice advises patients who have had NAION to discuss continued use with a clinician. Clinicians considering discontinuation are advised to weigh whether the benefits clearly outweigh the risk.
The alert does not establish how often NAION occurs among GLP-1 RA users or how much the risk may differ from that in people who do not use the medicines. It identifies a potential risk and does not predict whether an individual patient will develop the condition.
Products Worth Considering
LEVOIT Vital 200S-P Smart Air Purifier for Large Rooms up to 1875 ft², Quiet 27 dB Operation, AHAM VERIFIDE Certified, Air Quality Monitor,
Garmin Forerunner 265S 42 mm GPS Running Watch, Light Pink and Powder Gray
Withings Body Scan Smart Scale with Segmental Body Composition and ECG, Black
As an affiliate, we earn on qualifying purchases.
How GLP-1 Medicines Are Used
GLP-1 RAs mimic the effects of glucagon-like peptide-1, a hormone released by the intestine. According to the FDA, the hormone helps lower blood glucose after eating and acts in parts of the brain that control appetite and food intake. The medications are used for type 2 diabetes and weight management.
The FDA describes NAION as a rare condition and says its underlying cause is not completely understood. Risk factors may include smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease. The agency also notes that after NAION occurs in one eye, the risk of it occurring in the other eye is increased. These factors are listed as possible risks for NAION generally; the notice does not say they explain the potential association with GLP-1 RAs.
Risk Size and Evidence Details
The supplied FDA notice does not give a numerical risk estimate, describe the number of cases behind the safety action, or specify how risk compares across individual GLP-1 RA products. It also does not establish that the medicines caused the reported condition. The wording is limited to a potential increased risk.
The notice does not identify a deadline for manufacturers to complete the labeling changes or explain when updated labels will appear across products. It also does not provide a separate recommendation for patients without symptoms beyond awareness of the potential risk and contacting a health professional if vision changes occur.
Label Updates and Clinical Follow-Up
Manufacturers, described by the FDA as application holders, are required to add the NAION information to the Warnings and Precautions section of their GLP-1 RA labeling. The FDA notice supplied here does not state a completion timetable, so the timing of updated packaging and prescribing information remains unclear.
Patients taking these medicines should follow the FDA’s symptom guidance and seek prompt professional advice for sudden, painless vision loss or other listed visual disturbances. Clinicians are advised to refer suspected cases to an ophthalmologist and to weigh the benefits and risks of continuing treatment if NAION develops. The agency’s communication does not direct patients to stop a GLP-1 RA on their own.
Key Questions
What is the FDA requiring?
The FDA is requiring application holders for all GLP-1 RA medications to add information about a potential increased risk of NAION to the Warnings and Precautions section of labeling.
What is NAION?
NAION is a rare condition involving reduced blood flow to the front part of the optic nerve. It can cause sudden, painless vision loss in one eye, which may be permanent.
What symptoms should prompt a call to a health professional?
The FDA lists sudden painless vision loss, blurred or missing areas of vision, blind spots or tunnel vision, distorted colors, and reduced central sharpness. It advises patients to contact a health care professional right away if these occur.
Should patients stop taking their GLP-1 medication?
The FDA notice does not tell all patients to stop treatment. Anyone who has had NAION should discuss whether to continue or stop with a health care professional; clinicians should consider the benefits and risks if NAION develops.
How much does GLP-1 treatment increase the risk?
The supplied FDA communication describes a potential increased risk but provides no numerical estimate or comparison baseline. It does not establish that GLP-1 RAs cause NAION.
Source: fda.gov
